Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 4, Issue 9, 2014, Pages

  Zugmaier, G ^a   Topp, M S ^b   Alekar, S ^c   Viardot, A ^d   Horst, H A ^e   Neumann, S ^e   Stelljes, M ^f   Bargou, R C ^b   Goebeler, M ^b   Wessiepe, D ^g   Degenhard, E ^a   Gokbuget N ^h   Klinger, M ^a  

^a Amgen Research GmbH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c AMGEN INC   (United States)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g Metronomia GmbH   (Germany)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; PRE B LYMPHOCYTE; PRIMARY IMMUNE RESPONSE; QUANTITATIVE ANALYSIS; SECONDARY IMMUNE RESPONSE; BLOOD; CLINICAL TRIAL; FEMALE; MALE; PHASE 2 CLINICAL TRIAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; MALE; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84925461494     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.64     Document Type: Letter

References (15)

1. Bargou R, Leo E, Zugmaier G., Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
2. Topp MS, Gokbuget N, Zugmaier G., Degenhard E, Goebeler ME, Klinger M et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120: 5185-5187.
3. Topp MS, Kufer P, Gokbuget N., Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lympho-blastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498.
4. Murphy K. Janeway's Immunobiology Vol 1. New York City: Garland Science-Taylor & Francis, 2011.
5. van Tilburg CM, Bierings MB, Berbers G.A., Wolfs TF, Pieters R, Bloem AC et al. Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases. Pediatr Blood Cancer 2012; 58: 701-707.
6. Venhoff N, Effelsberg NM, Salzer U, Warnatz K., Peter HH, Lebrecht D et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012; 7: e37626.
7. Bluml S, McKeever K, Ettinger R., Smolen J, Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013; 15(suppl 1): S4.
8. Diwakar L, Gorrie S, Richter A., Chapman O, Dhillon P, Al-Ghanmi F et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010; 63: 275-277.
9. Dunleavy K, Reiter BLW, Grant CM, Shovlin M, Wright G.W., Fleisher TA et al. Rituximab Is associated with prolonged immunoglobulin deficiency in newly diagnosed patients with aggressive B-cell lymphoma receiving immunochem-otherapy. Blood 2010; 116: abstr 2881.
10. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immuno-globulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13: 106-111.
11. Walker AR, Kleiner A, Rich L., Conners C, Fisher RI, Anolik J et al. Profound hypo-gammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008; 26: 431-433.
12. Irie E, Shirota Y, Suzuki C., Tajima Y, Ishizawa K, Kameoka J et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010; 91: 501-508.
13. Kasamon YL, Jones RJ, Brodsky R.A., Fuchs EJ, Matsui W, Luznik L et al. Immuno-logic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol 2010; 21: 1203-1210.
14. Nishio M, Fujimoto K, Yamamoto S., Endo T, Sakai T, Obara M et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 2007; 137: 349-354.
15. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R., Marcus RE, Wolf M et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853-2858.